Conducting electrospun fibres with polyanionic grafts as highly selective, label-free, electrochemical biosensor with a low detection limit for non-Hodgkin lymphoma gene

2018 ◽  
Vol 100 ◽  
pp. 549-555 ◽  
Author(s):  
Thomas E. Kerr-Phillips ◽  
Nihan Aydemir ◽  
Eddie Wai Chi Chan ◽  
David Barker ◽  
Jenny Malmström ◽  
...  
Keyword(s):  
Detection Limit ◽  
Hodgkin Lymphoma ◽  
Electrochemical Biosensor ◽  
Label Free ◽  
Low Detection Limit ◽  
Non Hodgkin Lymphoma ◽  
Selective Label

Fiber-optics: a new route towards ultra-low detection limit label-free biosensing

2019 ◽  
Author(s):  
Pablo Zubiate ◽  
Desiree Santano ◽  
Aitor Urrutia ◽  
Carlos R. Zamarreño ◽  
Silvia Díaz ◽  
...  
Keyword(s):  
Detection Limit ◽  
Fiber Optics ◽  
Label Free ◽  
Low Detection Limit

A nanofluidic device for ultrasensitive and label-free detection of tetracycline in association with γ-cyclodextrin and GO

2021 ◽  
Vol 13 (15) ◽  
pp. 1832-1838
Author(s):  
Jiaxi Cheng ◽  
Fenghua Jiang ◽  
Siqi Zhang
Keyword(s):  
Detection Limit ◽  
Water Samples ◽  
Recovery Rate ◽  
Label Free ◽  
Detection Range ◽  
Low Detection Limit ◽  
Sensing Platform ◽  
Label Free Detection ◽  
Nanofluidic Device

We develop a label-free, sensitive and selective nanochannel sensing platform for detection of TC. The nanosensor provided a low detection limit, a wide detection range and excellent recovery rate in different water samples.

Label-free colorimetric aptasensor for IgE using DNA pseudoknot probe

The Analyst ◽  
2014 ◽  
Vol 139 (13) ◽  
pp. 3347-3351 ◽  
Author(s):  
Chia-Chen Chang ◽  
Chen-Yu Chen ◽  
Xihong Zhao ◽  
Tzu-Heng Wu ◽  
Shih-Chung Wei ◽  
...  
Keyword(s):  
Detection Limit ◽  
High Selectivity ◽  
Colorimetric Assay ◽  
Simple Design ◽  
Label Free ◽  
Low Detection Limit ◽  
Structure Switching ◽  
Colorimetric Aptasensor

A simple design of a label-free colorimetric assay for IgE was demonstrated based on a structure-switching aptamer with a low detection limit of 0.2 nM and high selectivity.

Studies on relativity of p73 gene methylation and non-Hodgkin lymphoma

2010 ◽  
Vol 34 (8) ◽  
pp. S48-S48
Author(s):  
Jing‑Hong Pei ◽  
Sai‑Qun Luo ◽  
Jiang‑Hua Chen ◽  
Hua‑Wu Xiao ◽  
Wei‑Xin Hu
Keyword(s):  
Hodgkin Lymphoma ◽  
Gene Methylation ◽  
Non Hodgkin Lymphoma ◽  
P73 Gene

Evaluation of R-CHOP and R-CVP in the treatment of elderly patient with non-Hodgkin lymphoma

MedPharmRes ◽  
2019 ◽  
Vol 3 (3) ◽  
pp. 1-6
Author(s):  
Truc Phan ◽  
Tram Huynh ◽  
Tuan Q. Tran ◽  
Dung Co ◽  
Khoi M. Tran
Keyword(s):  
Elderly Patients ◽  
Hodgkin Lymphoma ◽  
B Cell Lymphoma ◽  
Complete Response ◽  
The Elderly ◽  
Free Survival ◽  
Non Hodgkin Lymphoma ◽  
Common Sign ◽  
Related Mortality

Introduction: Little information is available on the outcomes of R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) in treatment of the elderly patients with non-Hodgkin lymphoma (NHL), especially in Vietnam. Material and methods: All patients were newly diagnosed with CD20-positive non-Hodgkin lymphoma (NHL) at Blood Transfusion and Hematology Hospital, Ho Chi Minh city (BTH) between 01/2013 and 01/2018 who were age 60 years or older at diagnosis. A retrospective analysis of these patients was perfomed. Results: Twenty-one Vietnamese patients (6 males and 15 females) were identified and the median age was 68.9 (range 60-80). Most of patients have comorbidities and intermediate-risk. The most common sign was lymphadenopathy (over 95%). The proportion of diffuse large B cell lymphoma (DLBCL) was highest (71%). The percentage of patients reaching complete response (CR) after six cycle of chemotherapy was 76.2%. The median follow-up was 26 months, event-free survival (EFS) was 60% and overall survival (OS) was 75%. Adverse effects of rituximab were unremarkable, treatment-related mortality accounted for less than 10%. There was no difference in drug toxicity between two regimens. Conclusions: R-CHOP, R-CVP yielded a good result and acceptable toxicity in treatment of elderly patients with non-Hodgkin lymphoma. In patients with known cardiac history, omission of anthracyclines is reasonable and R-CVP provides a competitive complete response rate.

Sign in / Sign up

Export Citation Format

Share Document